ACRS Aclaris Therapeutics, Inc.

28.88
0  0%
Previous Close 28.98
Open 28.98
Price To book 7.65
Market Cap 618.96M
Shares 21,432,000
Volume 387,662
Short Ratio 6.77
Av. Daily Volume 219,859

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
ATI-50002
Patchy alopecia areata
Phase 2 trial to be initiated 2H 2017.
ATI-50001
Alopecia totalis and alopecia universalis
NDA filing announced February 27, 2017.
A-101
Seborrheic keratosis (SK)
Phase 2 data released August 2016. Plans to initiate two Phase 2 trials in mid-2017.
A-101
Common warts (verruca vulgaris)

Latest News

  1. ACLARIS THERAPEUTICS, INC. Financials
  2. Edited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT
  3. Aclaris reports 4Q loss
  4. Aclaris reports 4Q loss
  5. ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  6. Q4 2016 Aclaris Therapeutics Inc Earnings Release - Before Market Open
  7. Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  8. Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis – a Common Skin Condition
  9. Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5%
  10. Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
  11. Aclaris Therapeutics to Attend Upcoming Investor Conferences
  12. Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
  13. ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
  14. Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors
  15. Why Aclaris Therapeutics (ACRS) Stock Might be a Great Pick
  16. Aclaris to Present at 35th Annual J.P. Morgan Healthcare Conference
  17. Aclaris Therapeutics Inc (ACRS) Hedge Funds Are Snapping Up
  18. Why Aclaris (ACRS) Could Be Positioned for a Surge
  19. Aclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5%
  20. Edited Transcript of ACRS earnings conference call or presentation 3-Nov-16 12:30pm GMT